enGene Secures Expanded $125 Million Debt Facility from Hercules Capital

Reuters01-21

enGene Secures Expanded $125 Million Debt Facility from Hercules Capital

enGene Holdings Inc., a clinical-stage genetic medicines company, has announced an amendment to its existing loan and security agreement with Hercules Capital, Inc., increasing its debt facility to up to $125 million. Under the revised terms, enGene has received an initial $25 million to refinance existing debt, with access to three additional tranches totaling $75 million contingent on achieving certain clinical, regulatory, and commercial milestones. An additional tranche of up to $25 million may be made available at Hercules' discretion. The funding strengthens enGene’s balance sheet as it prepares for a Biologics License Application to the FDA for detalimogene voraplasmid in the second half of 2026 and a potential commercial launch in 2027. All outstanding principal and accrued interest are to be repaid by January 1, 2030, unless extended under the loan agreement terms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260120638572) on January 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605142413?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-21 06:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605142413","market":"nz","top_or_hot":-1,"title":"enGene Secures Expanded $125 Million Debt Facility from Hercules Capital","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      enGene Secures Expanded $125 Million Debt Facility from Hercules Capital\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        enGene Holdings Inc., a clinical-stage genetic medicines company, has announced an amendment to its existing loan and security agreement with <a href=\"https://laohu8.com/S/HCXZ\">Hercules Capital, Inc.</a>, increasing its debt facility to up to $125 million. Under the revised terms, enGene has received an initial $25 million to refinance existing debt, with access to three additional tranches totaling $75 million contingent on achieving certain clinical, regulatory, and commercial milestones. An additional tranche of up to $25 million may be made available at Hercules' discretion. The funding strengthens enGene’s balance sheet as it prepares for a Biologics License Application to the FDA for detalimogene voraplasmid in the second half of 2026 and a potential commercial launch in 2027. All outstanding principal and accrued interest are to be repaid by January 1, 2030, unless extended under the loan agreement terms.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260120638572) on January 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>enGene Secures Expanded $125 Million Debt Facility from Hercules Capital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nenGene Secures Expanded $125 Million Debt Facility from Hercules Capital\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-21 06:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      enGene Secures Expanded $125 Million Debt Facility from Hercules Capital\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        enGene Holdings Inc., a clinical-stage genetic medicines company, has announced an amendment to its existing loan and security agreement with <a href=\"https://laohu8.com/S/HCXZ\">Hercules Capital, Inc.</a>, increasing its debt facility to up to $125 million. Under the revised terms, enGene has received an initial $25 million to refinance existing debt, with access to three additional tranches totaling $75 million contingent on achieving certain clinical, regulatory, and commercial milestones. An additional tranche of up to $25 million may be made available at Hercules' discretion. The funding strengthens enGene’s balance sheet as it prepares for a Biologics License Application to the FDA for detalimogene voraplasmid in the second half of 2026 and a potential commercial launch in 2027. All outstanding principal and accrued interest are to be repaid by January 1, 2030, unless extended under the loan agreement terms.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260120638572) on January 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HTGC","symbol_name":"海格投资","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL8gJ3Yb:1","article_id":"2605142413","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605142413","pubTimestamp":1768948516,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"enGene Holdings Inc., a clinical-stage genetic medicines company, has announced an amendment to its existing loan and security agreement with Hercules Capital, Inc., increasing its debt facility to up to $125 million. Under the revised terms, enGene has received an initial $25 million to refinance existing debt, with access to three additional tranches totaling $75 million contingent on achieving certain clinical, regulatory, and commercial milestones. An additional tranche of up to $25 million may be made available at Hercules' discretion. The funding strengthens enGene’s balance sheet as it prepares for a Biologics License Application to the FDA for detalimogene voraplasmid in the second half of 2026 and a potential commercial launch in 2027. All outstanding principal and accrued interest are to be repaid by January 1, 2030, unless extended under the loan agreement terms.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HTGC":"海格投资","BK4135":"资产管理与托管银行","BK4139":"生物科技","ENGN":"ENGENE HOLDINGS INC"},"translate_title":"enGene从Hercules Capital获得1.25亿美元的扩大债务融资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENGN":0.9,"HTGC":0.9},"content_text":"enGene Secures Expanded $125 Million Debt Facility from Hercules Capital\n    \n\n        enGene Holdings Inc., a clinical-stage genetic medicines company, has announced an amendment to its existing loan and security agreement with Hercules Capital, Inc., increasing its debt facility to up to $125 million. Under the revised terms, enGene has received an initial $25 million to refinance existing debt, with access to three additional tranches totaling $75 million contingent on achieving certain clinical, regulatory, and commercial milestones. An additional tranche of up to $25 million may be made available at Hercules' discretion. The funding strengthens enGene’s balance sheet as it prepares for a Biologics License Application to the FDA for detalimogene voraplasmid in the second half of 2026 and a potential commercial launch in 2027. All outstanding principal and accrued interest are to be repaid by January 1, 2030, unless extended under the loan agreement terms.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260120638572) on January 20, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605142413","isCrawlerRequest":true}